Kamada (NASDAQ:KMDA) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDA) in a report released on Thursday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, May 9th.

Kamada Stock Performance

Shares of KMDA stock opened at $5.00 on Thursday. The firm has a market cap of $287.40 million, a price-to-earnings ratio of 21.74 and a beta of 1.06. Kamada has a 52 week low of $4.08 and a 52 week high of $6.53. The firm’s 50-day simple moving average is $5.27 and its two-hundred day simple moving average is $5.64.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.02). Kamada had a return on equity of 5.50% and a net margin of 8.33%. The company had revenue of $37.74 million during the quarter, compared to the consensus estimate of $38.01 million. Analysts forecast that Kamada will post 0.26 earnings per share for the current year.

Hedge Funds Weigh In On Kamada

A number of institutional investors have recently made changes to their positions in KMDA. EWA LLC bought a new position in shares of Kamada during the 4th quarter valued at $68,000. Calton & Associates Inc. bought a new position in shares of Kamada during the 4th quarter valued at $111,000. Y.D. More Investments Ltd grew its holdings in shares of Kamada by 107.1% during the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 15,000 shares during the last quarter. Aristides Capital LLC grew its holdings in shares of Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 16,635 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.